A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
← catalyst calendarNCT05984277 · readout in 924 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
895actual
Sites
247
Countries
Argentina, Australia, Austria +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-24 | actual | When the study began enrolling |
| Primary completion | 2029-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Non-small Cell Lung Cancer
Interventions
- Drug: Volrustomig
- Drug: Pembrolizumab
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Pemetrexed
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)
measured Up to approximately 6 years
Overall Survival (OS), in PD-L1-negative participants.
measured Up to approximately 6 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed